UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/600/0.1/18.06.25 | Real-time BOERSE MUENCHEN 13:42:23 2024-05-31 EDT | ||
| 1.71 EUR | +11.76% |
|
| Current month | +104.00% | ||
| 1 month | +104.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 1.71 | +11.76% |
| 24-05-30 | 1.53 | -3.16% |
| 24-05-29 | 1.58 | 0.00% |
| 24-05-28 | 1.58 | -16.40% |
| 24-05-27 | 1.89 | +2.16% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 01:42 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC7U38 |
| ISIN | DE000HC7U383 |
| Date issued | 2023-06-30 |
| Strike | 600 $ |
| Maturity | 2025-06-18 (383 Days) |
| Parity | 10 : 1 |
| Emission price | 1.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.77 € |
|---|---|
| Lowest since issue | 0.66 € |
| Spread | 0.03 € |
| Spread % | 1.72% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
443
USD
Average target price
463.5
USD
Spread / Average Target
+4.62%
- Stock Market
- Warrants
- Warrant
